TheStreet's Jim Cramer, sporting a Phillies baseball cap to mark baseball season's Opening Day, talked about Salesforce.com (CRM) pharmaceutical companies, and other stocks from the floor of the New York Stock Exchange on Monday. A viewer wanted to know if it was too late to buy Salesforce.com and Cramer said it's still a buy, because the company keeps signing on new clients. He also said Adobe (ADBE) is a buy. Another viewer wanted to know if now is a good time to own pharmaceutical companies Eli Lilly (LLY) and Bristol Myers (BMY) . Cramer said Lilly has been a bit disappointing, and the portfolio he manages, Action Alerts PLUS, sold the stock. Cramer notes Biogen (BIIB) and Allergan (AGN) have also been weak. 'The drug companies are public enemy number one,' said Cramer. Cramer says he likes Bristol, but no need to rush in to buy it in the current environment. Cramer was also asked about First Solar (FSLR) , and he said if the stock comes in that could be a chance to buy it. He also talked about the problems at SunEdison (SUNE) . Finally, Cramer was asked if FireEye (FEYE) is a buy considering all the hacking in the news. Cramer said the hacking play is Palo Alto Networks (PANW) or CyberArk (CYBR) but he noted they are expensive stocks. Cramer also talked fondly about the time he spent watching the Phillies over the years. Viewers can submit questions to Cramer's Facebook page or on Twitter, use hashtag CramerQ.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.